Trial Profile
Phase II Open-label, Multicentre, Randomized Trial of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus Paclitaxel in Combination With HER2 Blockade for Postmenopausal Patients With Hormone Receptor Positive/HER2 Positive Early Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2023
Price :
$35
*
At a glance
- Drugs Letrozole (Primary) ; Palbociclib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Paclitaxel
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms TOUCH
- 24 Jul 2023 Status changed from active, no longer recruiting to completed.
- 18 May 2023 This trial has been completed in Belgium (End Date: 20 Apr 2023), according to European Clinical Trials Database record.
- 20 Apr 2023 Planned End Date changed from 1 Mar 2023 to 30 Apr 2023.